Results 71 to 80 of about 104,861 (298)

Homologous recombination deficiency and ovarian cancer [PDF]

, 2016
The discovery that PARP inhibitors block an essential pathway of DNA repair in cells harbouring a BRCA mutation has opened up a new therapeutic avenue for high-grade ovarian cancers.
Drew, Y, Kristeleit, RS, Ledermann, JA
core   +1 more source

Cell‐cycle‐specific lesion evolution rather than inhibition of double‐strand‐break repair underpins cisplatin radiosensitization

Molecular Oncology, EarlyView.
We analyze cisplatin–DNA adducts (CDAs) and double‐strand breaks (DSBs) in a cell‐cycle‐dependent manner. We find that CDAs form similarly across all cell cycle phases. DSBs arise only in S‐phase. CDAs might not directly impair DSB repair, but S‐phase DSB lesions evolve in the presence of CDAs and disrupt repair in G2, also causing radiosensitization ...
Ye Qiu, Xixi Lin, Emil Mladenov, Veronika Mladenova, Jürgen Thomale, Ali Sak, Yao Wang, Yunxuan Deng, Eleni Gkika, Martin Stuschke, George Iliakis   +10 more
wiley   +1 more source

Posttranscriptional regulation of PARG mRNA by HuR facilitates DNA repair and resistance to PARP inhibitors [PDF]

, 2017
The majority of pancreatic ductal adenocarcinomas (PDAC) rely on the mRNA stability factor HuR (ELAV-L1) to drive cancer growth and progression. Here, we show that CRISPR-Cas9–mediated silencing of the HuR locus increases the relative sensitivity of PDAC
Brody, Jonathan R., Chand, Saswati N., Cozzitorto, Joseph A., Jiang, Wei, Knudsen, Karen E., Lal, Shruti, Londin, Eric R., Meisner-Kober, Nicole, Nevler, Avinoam, Pascal, John M, Pishvaian, Michael J., Romeo, Carmella, Sanan, Akshay R., Schiewer, M. J., Scolaro, Laura, Winter, Jordan M., Yeo, Charles, Zarei, Mahsa   +17 more
core   +1 more source

Medical treatment of early stage and rare histological variants of epithelial ovarian cancer [PDF]

, 2015
Epithelial ovarian cancer is often considered a single pathological entity, but increasing evidence suggests that it is rather a group of different neoplasms, each with unique pathological characteristics, molecular features, and clinical behaviours ...
Biglia, Nicoletta, CODACCI PISANELLI, Giovanni, Colombo, Nicoletta, Cont, Nicoletta Tomasi, D'Alonzo, Marta, Ferrero, Annamaria, Peccatori, Fedro Alessandro   +6 more
core   +3 more sources

Nanoparticle Formulations of Poly (ADP-ribose) Polymerase Inhibitors for Cancer Therapy

Frontiers in Chemistry, 2020
A number of poly(ADP-ribose) polymerase (PARP) inhibitors have been recently approved for clinical use in BRCA mutated and other cancers. However, off-target toxicity of PARP inhibitors and the emergence of drug resistance following prolonged ...
Bijay Singh, Bijay Singh, Shicheng Yang, Shicheng Yang, Apurva Krishna, Apurva Krishna, Srinivas Sridhar, Srinivas Sridhar, Srinivas Sridhar, Srinivas Sridhar, Srinivas Sridhar   +10 more
doaj   +1 more source

Dual Inhibitors of PARPs and ROCKs [PDF]

ACS Omega, 2018
Recent network and system biology analyses suggest that most complex diseases are regulated by robust and highly interconnected pathways that could be better modulated by small molecules binding to multiple biological targets. These pieces of evidence recently led to devote efforts on identifying single chemical entities that bind to two different ...
Albert A. Antolín, Jordi Mestres
openaire   +5 more sources

Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining

Molecular Oncology, EarlyView.
IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis, Jack V. Mills, Wojciech Niedzwiedz, Valentine M. Macaulay   +3 more
wiley   +1 more source

BH3 mimetic ABT-737 sensitizes colorectal cancer cells to ixazomib through MCL-1 downregulation and autophagy inhibition. [PDF]

, 2016
The proteasome inhibitor MLN9708 is an orally administered drug that is hydrolyzed into its active form, MLN2238 (ixazomib). Compared with Bortezomib, MLN2238 has a shorter proteasome dissociation half-life and a lower incidence and severity of ...
Barkhouse, Darryll, Li, Guichao, Lu, Bo, Wan, Juefeng, Xiao, Sheng, Yang, Lifeng, Zhang, Zhen, Zhu, Ji   +7 more
core   +2 more sources

PARP inhibitors induce a senescence phenotype in non‐small cell lung carcinoma cell lines

FEBS Open Bio, EarlyView.
Talazoparib is the most potent inducer of senescence among different PARP1 inhibitors in human NSCLC cells. In the absence of PARP, no senescence phenotype was observed, demonstrating that PARP1 is necessary for the induction of senescence by this inhibitor.
Camille Huart, Manon Van den Abbeel, Christoph Schifflers, Karim Bouhjar, Andrea Scarmelotto, Alexis Khelfi, Anne‐Catherine Wera, Carine Michiels   +7 more
wiley   +1 more source

The kinesin Eg5 inhibitor K858 induces apoptosis but also survivin-related chemoresistance in breast cancer cells [PDF]

, 2016
Inhibitors of kinesin spindle protein Eg5 are characterized by pronounced antitumor activity. Our group has recently synthesized and screened a library of 1,3,4-thiadiazoline analogues with the pharmacophoric structure of K858, an Eg5 inhibitor.
CARRADORI, Simone, DE IULIIS, FRANCESCA, giantulli, sabrina, GIUFFRIDA, Anna, MILANA, Bernardina, SALERNO, GERARDO, SCARPA, Susanna, SILVESTRI, Ida, Taglieri, Ludovica   +8 more
core   +1 more source